Soligenix, INC S-1 registration statements

Soligenix, a late-stage biopharmaceutical company, is offering up to $8.0 million in common stock and warrants to address its liquidity concerns and regain compliance with Nasdaq's minimum stockholders' equity requirement.

Soligenix is registering up to 1,054,688 shares of common stock for resale by selling stockholders following the exercise of warrants.

Soligenix, Inc. plans to raise up to $10 million through a public offering of common stock and warrants to fund research, development, and general corporate purposes.

Soligenix, a late-stage biopharmaceutical company, plans to raise up to $10 million through a public offering of common stock and warrants to fund research, development, and commercialization activities.

Soligenix, a late-stage biopharmaceutical company, announces a proposed public offering to raise up to $10 million through the sale of common stock and warrants.